ArticleDiabetes, obesity & metabolism2021

Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.

Odette Reifsnider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.